(RPTX) Repare Therapeutics - Ratings and Ratios

Repare Therapeutics Inc. (NASDAQ:RPTX) is a clinical-stage precision oncology company specializing in the discovery and development of synthetic lethality-based therapeutics. Leveraging its proprietary SNIPRx platform—a genome-wide, CRISPR-enabled technology—the company identifies and validates targets associated with genomic instability, particularly DNA damage repair. This approach allows Repare to build a robust pipeline of precision oncology treatments tailored to specific molecular vulnerabilities in cancer cells.

The companys lead candidate, Camonsertib (RP-3500), is an oral small molecule inhibitor currently in Phase ½ clinical trials for solid tumors characterized by DNA damage repair-related genomic alterations. Additional pipeline assets include Lunresertib (RP-6306), a PKMYT1 inhibitor in Phase I/Ib trials for tumors with CCNE1 amplification; RP-1664, an oral PLK4 inhibitor in Phase 1 trials targeting TRIM37-amplified or overexpressed solid tumors; and RP-3467, a polymerase theta ATPase inhibitor targeting BRCA mutations and other genomic alterations.

Repare has established strategic collaborations to enhance its development capabilities. These include agreements with Hoffmann-La Roche, Bristol-Myers Squibb, and Ono Pharmaceutical, as well as a cooperative research and development agreement with the US National Cancer Institute. Additionally, the company has partnered with Foundation Medicine for genomic profiling and Debiopharm to explore synthetic lethal combinations of PKMYT1 and WEE1 inhibition in cancer. Founded in 2016 and headquartered in Montreal, Canada, Repare is advancing a highly targeted approach to cancer therapy, focusing on genomic-defined patient populations.

Based on the provided data, here is a 3-month forecast:

Average Volume 20d: 184,645 Last Price: 1.21 SMA 20: 1.23 SMA 50: 1.26 SMA 200: 2.80 ATR: 0.09

Market Cap: 51.01M USD P/E: 0.00 P/E Forward: 0.00 P/B: 0.30 P/S: 0.77 RoE: -48.04

3-Month Forecast: The stock is currently trading below its 20-day and 50-day SMAs but above its 200-day SMA, indicating potential bearish momentum in the near term. Support levels may form near the 200-day SMA at 2.80. The low ATR of 0.09 suggests limited volatility, but the negative RoE of -48.04 signals ongoing operational challenges. The low P/B ratio of 0.30 and P/S of 0.77 may indicate undervaluation, but this must be weighed against the lack of profitability. The next 3 months will likely see continued pressure on the stock price unless positive clinical trial results or partnerships materialize to drive sentiment.